Bioxytran (BIXT) Depreciation & Amortization (CF) (2010 - 2018)
Bioxytran (BIXT) posted Depreciation & Amortization (CF) of $4363.0 for Q2 2018, little changed sequentially from $4363.0 in Q1 2018, and down 1.56% YoY from $4432.0 in Q2 2017.
Bioxytran (BIXT) Depreciation & Amortization (CF) (2010 - 2018) Analysis & Trends
Bioxytran has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $4363.0 in Q2 2018.
- Quarterly Depreciation & Amortization (CF) fell 1.56% year-over-year to $4363.0 in Q2 2018, while the trailing twelve-month figure through Mar 2019 was $4363.0 (down 75.12% YoY) and the FY2017 annual result came in at $17536.0, down 36.53% from the prior year.
- Depreciation & Amortization (CF) held at $4363.0 in Q2 2018 per BIXT's latest filing, from $4363.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $14548.0 in Q2 2014 and troughed at $4363.0 in Q1 2017.
- A 5-year average of $9270.1 and a median of $9009.0 in 2015 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2014 and 2016: Depreciation & Amortization (CF) surged 463.44% in 2014, then sank 67.78% in 2016.
- Over 5 years, Depreciation & Amortization (CF) stood at $14548.0 in 2014, then decreased by 23.45% to $11137.0 in 2015, then slumped by 59.89% to $4467.0 in 2016, then retreated by 2.31% to $4364.0 in 2017, then declined by 0.02% to $4363.0 in 2018.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $4363.0, $4363.0, and $4364.0 for Q2 2018, Q1 2018, and Q4 2017 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 4,363.00 |
| Jun 30, 2018 | 4,363.00 |
| Mar 31, 2018 | 4,363.00 |
| Mar 31, 2018 | 4,363.00 |
| Dec 31, 2017 | 4,364.00 |
| Dec 31, 2017 | 4,364.00 |
| Sep 30, 2017 | 4,377.00 |
| Sep 30, 2017 | 4,377.00 |
| Jun 30, 2017 | 4,432.00 |
| Jun 30, 2017 | 4,432.00 |
| Mar 31, 2017 | 4,363.00 |
| Mar 31, 2017 | 4,363.00 |
| Dec 31, 2016 | 4,467.00 |
| Dec 31, 2016 | 4,467.00 |
| Sep 30, 2016 | 4,687.00 |
| Sep 30, 2016 | 4,687.00 |
| Jun 30, 2016 | 6,881.00 |
| Jun 30, 2016 | 6,881.00 |
| Mar 31, 2016 | 11,593.00 |
| Mar 31, 2016 | 11,593.00 |